Boston Life Sciences

What Boston Life Sciences does

Boston Life Sciences, Inc. was a clinical-stage biotechnology company founded in 2005 and headquartered at 85 Main Street, Hopkinton, Massachusetts, focused on research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. Its portfolio centered on radiopharmaceutical imaging agents — ALTROPANE®, a 123Iodine-based SPECT agent for early diagnosis of Parkinson's Disease and objective diagnosis of ADHD, and FLUORATEC™, a Technetium-99m-based alternative — together with two therapeutic candidates: O-1369, a novel dopamine transporter (DAT) blocker for Parkinson's Disease, and Inosine, a nerve growth factor approach targeting stroke and spinal cord injury. Underlying technology combined proprietary small-molecule radiochemistry (123I and 99mTc labeling) with CNS-targeted pharmacology, and the lead asset ALTROPANE had advanced to a Phase III POET-1 trial in Parkinson's Disease that was terminated early in 2006 to evaluate the full data set, while a Phase II in ADHD and three pre-clinical assets (FLUORATEC™, O-1369, Inosine) remained in the pipeline.

The company's business model was pre-commercial and dependent on equity financing: it raised $12.7 million through a private placement of common stock in 2006, with intended future revenue from licensing or commercialization of diagnostic imaging agents to hospitals and imaging centers and from therapeutic licensing or partnership deals with larger pharmaceutical companies. Target end users were patients with Parkinson's Disease, ADHD, stroke, spinal cord injury, and related CNS conditions, reached indirectly through clinical trial sites, neurologists, and psychiatrists rather than via a direct sales force. Operating status is flagged as closed, with no commercial revenue, no active pipeline progression recorded after 2006, and the corporate website last substantively updated in Winter 2005 — indicating the company did not transition beyond clinical development.

Name

Boston Life Sciences

Legal name

Boston Life Sciences, Inc.

Website

https://bostonlifesciences.com

Company type

Private

Founded year

2005

Operating status

Closed

Headcount range

1–10 employees

Short description

Boston Life Sciences is a clinical-stage biotechnology company developing radiopharmaceutical imaging agents (ALTROPANE®, FLUORATEC™) and therapeutics for CNS disorders including Parkinson's Disease, ADHD, stroke, and spinal cord injury. The Hopkinton, Massachusetts-based firm has ceased active operations.

Ownership category

akta.pro rank

Product category

CNS Therapeutics and Diagnostics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Movement Disorders (Parkinson’s, Tremor, Dystonia) (HLAKAIAC), Neuromuscular Medicine (ALS, Myasthenia, Neuropathy) (HLAKAIAD)

Keywords

• CNS diagnostic imaging
• Radiopharmaceutical agents
• Parkinson's disease treatment
• ADHD diagnostic imaging
• Neurodegenerative therapeutics

Headquarters

HQ city

Hopkinton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Diagnostic Imaging Agents: Revenue from commercialization of diagnostic imaging products (ALTROPANE, FLUORATEC) for CNS diseases. These radioactive pharmaceutical agents would be sold to hospitals, imaging centers, and healthcare providers for diagnostic purposes.
2. Therapeutic Products: Revenue from therapeutic products (O-1369, Inosine) for treatment of Parkinson's Disease, stroke, and spinal cord injury. May be realized through direct commercialization, licensing, or acquisition by pharmaceutical partners.
3. Private Placement Financing: The company raised $12.7 million through a private placement of common stock, indicating reliance on equity financing to fund clinical development operations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Boston Life Sciences is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) diseases. Its portfolio includes the radiopharmaceutical imaging agents ALTROPANE® (123I-based, for Parkinson's Disease and ADHD) and FLUORATEC™ (Technetium-99m-based, for Parkinson's Disease and ADHD), along with therapeutic candidates Inosine (a nerve growth factor for stroke and spinal cord injury) and O-1369 (a novel Dopamine Transporter Blocker for Parkinson's Disease).

Product overview

Boston Life Sciences is a biotechnology company engaged in the research and clinical development of novel diagnostic and therapeutic products for Central Nervous System (CNS) diseases. The company's product portfolio consists of imaging agents and therapeutic candidates. ALTROPANE® is a 123I-Based imaging agent targeting early diagnosis of Parkinson's Disease and ADHD, currently in POET-1 Phase III trial for PD and Phase II for ADHD. Supporting the diagnostic pipeline are FLUORATEC™ (a Technetium-based imaging agent in pre-clinical stage) and therapeutic candidates Inosine (nerve growth factors for stroke and spinal cord injury) and O-1369 (a novel DAT Blocker for Parkinson's Disease).

Differentiator

Problem solved

Functional benefit

Brands

• ALTROPANE®: 123 I-Based imaging agent for the early diagnosis of Parkinson's Disease and Attention Deficit Hyperactivity Disorder (ADHD).
• FLUORATEC™

Quantifiable outcome

• ALTROPANE POET-1 Phase III trial results expected in Q3 2006
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• GE HealthCare: GE HealthCare manufactures and markets DaTscan (Ioflupane I-123), the leading FDA-approved SPECT imaging agent for Parkinson's disease diagnosis — the most direct competitor to ALTROPANE in PD imaging. Same target indication, similar radiopharmaceutical mechanism, and same nuclear medicine distribution channel.
• Eli Lilly (Avid Radiopharmaceuticals): Lilly acquired Avid Radiopharmaceuticals, developer of Amyvid (florbetapir F-18) and other CNS-targeted PET imaging agents. Direct competitor in CNS radiopharmaceutical imaging with established commercialization infrastructure and regulatory experience overlapping Boston Life Sciences' ALTROPANE/FLUORATEC approach.
• Lundbeck: Lundbeck is a specialty CNS pharmaceutical company with Parkinson's disease therapeutics (e.g., Northera for neurogenic orthostatic hypotension, Onapgo apomorphine infusion). Direct peer as a CNS-focused innovator pharma targeting overlapping neurology indications including movement disorders.
• Acadia Pharmaceuticals: Acadia developed Nuplazid (pimavanserin), the first FDA-approved therapy for Parkinson's disease psychosis. Closely comparable specialty CNS pharmaceutical company with novel mechanism compounds targeting Parkinson's and related CNS disorders.
• Intra-Cellular Therapies: Developed Caplyta (lumateperone), an FDA-approved CNS therapy for schizophrenia and bipolar depression. Specialty CNS pharmaceutical with novel-mechanism small molecules targeting neurology/psychiatry indications — directly comparable innovation profile to Boston Life Sciences' CNS pipeline.
• Sage Therapeutics: Sage developed Zurzuvae (zuranolone) for postpartum depression and previously had CNS-focused programs. Specialty CNS pharmaceutical company with novel-mechanism therapeutics addressing high-unmet-need neurology indications, similar clinical-development-stage profile to Boston Life Sciences during active operations.
• Cerevel Therapeutics: Cerevel is a clinical-stage CNS-focused biotechnology company developing novel therapies for Parkinson's disease and other neurology indications. Direct peer in CNS therapeutics innovation with overlapping PD target space to Boston Life Sciences' O-1369 DAT blocker.
• Acorda Therapeutics: Acorda developed Inbrija (levodopa inhalation) for Parkinson's OFF episodes and previously Ampyra for MS — a specialty CNS pharmaceutical company with late-stage and commercialized neurology products, providing direct comparability in CNS commercialization model.

Emerging players

• Voyager Therapeutics: Voyager develops gene therapy approaches for CNS disorders including Parkinson's disease. Emerging player with overlapping neurology therapeutic focus using novel modalities (AAV gene therapy) — comparable innovation-stage biotech targeting CNS indications overlapping Boston Life Sciences' pipeline.
• Neuralstem: Neuralstem developed novel small-molecule and cell therapy approaches for CNS conditions including spinal cord injury and stroke. Emerging player with overlapping preclinical-to-clinical stage CNS pipeline targeting nerve regeneration and repair — directly comparable to Boston Life Sciences' Inosine program.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/boston-life-sciences-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boston Life Sciences